Gómez-López, Sandra http://orcid.org/0000-0001-5163-6066
Whiteman, Zoe E. http://orcid.org/0000-0002-1098-6120
Janes, Sam M. http://orcid.org/0000-0002-6634-5939
Funding for this research was provided by:
Cancer Research UK (A27437)
Wellcome Trust (WT107963AIA)
Rosetrees Trust
Roy Castle Lung Cancer Foundation
Article History
Received: 3 February 2021
Accepted: 15 July 2021
First Online: 5 August 2021
Competing interests
: Paid advisory boards: 2018 and 2020 Astra-Zeneca; 2018 and 2019 BARD1 Life Sciences; 2018 Achilles Therapeutics; 2019 Johnson and Johnson (S.M.J.). Assistance or travel to meetings: Astra-Zeneca, ATS 2018 San Diego; Takeda, WCLC 2019 Barcelona (S.M.J.). Grant Investigator lead 2018-2028 GRAIL Inc; 2018 Owlstone (S.M.J.). Personal: Spouse works for and owns shares in Astra-Zeneca (S.M.J.). S.G.-L. and Z.E.W. declare no competing interests relating to this work.